ALLIANCE Commercialising a smart cardiac implant platform for the treatment of chronic cardiovascular disease
- Coordinator
- Aurigen Medical Limited, Ireland
- Runs
- 1 June 2023 to 30 June 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €4.0m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190188876
What the project is doing
In the project's own words, from its summary on CORDIS.
Every year chronic cardiac disease causes 3.9 million deaths in Europe, that’s a death every 8 seconds. Overall chronic cardiac disease is estimated to cost the EU €210 billion/yr, in direct healthcare costs. All chronic cardiac disease patients are at high risk of stroke, atrial fibrillation, &/or heart failureThe AuriGen platform is single minded in its focus on the leading causes of death in the developed world – Cardiovascular Diseases.
Allowing more complex patients to be treated more effectively, and at a lower cost per patient. AuriGen’s platform of 4 devices is built around our custom cardiac implant, to which we can add synergistic modules such as cardiac monitoring, ablation or both modules. Creating devices which are much more than the sum of their parts, this our key USP. Allowing AuriGen to efficiently & effectively manage the most expensive & sub-optimally treated patients, in a single, safe, fast minimally invasive procedure.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Aurigen Medical Limited | Dublin | Ireland | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI